Cepheid PT Raised to $43.00 at Jefferies Group (CPHD)
Jefferies Group hoisted their target price on shares of Cepheid (NASDAQ:CPHD) from $36.00 to $43.00 in a research note issued on Friday, Analyst Ratings Network.com reports. Jefferies Group’s target price points to a potential downside of 18.65% from the stock’s previous close.
Cepheid (NASDAQ:CPHD) opened at 52.86 on Friday. Cepheid has a 52-week low of $30.95 and a 52-week high of $54.45. The stock has a 50-day moving average of $47.00 and a 200-day moving average of $40.85. The company’s market cap is $3.586 billion.
Cepheid (NASDAQ:CPHD) last posted its quarterly earnings results on Friday, January 31st. The company reported ($0.15) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.04. The company had revenue of $113.30 million for the quarter, compared to the consensus estimate of $102.17 million. On average, analysts predict that Cepheid will post $0.01 earnings per share for the current fiscal year.
A number of other firms have also recently commented on CPHD. Analysts at Raymond James raised their price target on shares of Cepheid from $50.00 to $57.00 in a research note to investors on Friday. Separately, analysts at Oppenheimer raised their price target on shares of Cepheid from $43.00 to $54.00 in a research note to investors on Friday. Finally, analysts at UBS AG raised their price target on shares of Cepheid from $48.00 to $55.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $48.25.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.